Secondary Acute Myeloid Leukemia (Secondary AML, sAML) (DBCOND0041078)

Identifiers

Synonyms

Secondary Acute Myeloid Leukemia / Acute, secondary Myeloid Leukemia / Secondary Acute Myeloid Leukemia (AML)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00658814	Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	Azacitidine Gemtuzumab ozogamicin	treatment	2	active_not_recruiting
NCT04214249	BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Idarubicin Pembrolizumab	treatment	2	recruiting
NCT02727803	Personalized NK Cell Therapy in CBT	Activated natural killer cell therapy Aloe vera leaf Ascorbic acid Busulfan CD-16 NK-92 cells Clofarabine Cyclophosphamide Fludarabine Glycerin Mechlorethamine Natural Killer Cell Nicotinamide Rituximab Vitamin A	treatment	2	recruiting
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT03519984	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia	Cytarabine SEphB4-HSA Vincristine	treatment	1	terminated
NCT00898079	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer	No drug interventions	Not Available	Not Available	completed
NCT05780879	A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia	Venetoclax	treatment	2	recruiting
NCT04284787	BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia	Azacitidine Pembrolizumab Venetoclax	treatment	2	active_not_recruiting
NCT02658487	Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia	Cytarabine Vosaroxin	treatment	2	active_not_recruiting
NCT00112853	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Etoposide Tipifarnib	treatment	1	completed
NCT01005277	Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia	No drug interventions	Not Available	Not Available	completed
NCT05672147	CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia	No drug interventions	treatment	1	recruiting
NCT04518345	TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia	Azacitidine Dubermatinib	treatment	0	completed
NCT03365661	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Nogapendekin alfa	treatment	2	withdrawn
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT02583893	Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia	Cytarabine Etoposide Mitoxantrone Sirolimus	basic_science	2	completed
NCT00602771	Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia	Etoposide Tipifarnib	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT03041688	Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia	Decitabine Navtemadlin Venetoclax	treatment	1	active_not_recruiting
NCT00666588	Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Idarubicin	treatment	2	completed
NCT02323607	Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations	Cytarabine Daunorubicin Decitabine Pacritinib	treatment	1	completed
NCT01371656	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Levofloxacin	supportive_care	3	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01305200	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant	Calcium Phosphate	supportive_care	3	completed
NCT00703300	Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine Bortezomib Bortezomib D-mannitol Decitabine	treatment	1	completed
NCT00351975	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases	Azacitidine Belinostat	treatment	1	completed
NCT03878199	Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms	Cytarabine Daunorubicin Ruxolitinib	treatment	1 / 2	recruiting
NCT04269213	CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	Cytarabine Daunorubicin	treatment	2	recruiting
NCT02299518	Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Escitalopram Etoposide Mitoxantrone Selinexor	treatment	1	completed
NCT03226418	Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia	Azacitidine Cytarabine Daunorubicin Decitabine Glasdegib Idarubicin Venetoclax	treatment	2	active_not_recruiting
NCT05554419	Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)	Azacitidine Cytarabine Daunorubicin Venetoclax	treatment	2	not_yet_recruiting
NCT00039117	Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin	treatment	1	completed
NCT02530034	Hu8F4 in Treating Patients With Advanced Hematologic Malignancies	No drug interventions	treatment	1	active_not_recruiting
NCT02044796	Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Cladribine Cytarabine Filgrastim Mitoxantrone	treatment	1 / 2	completed
NCT00313586	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT03333486	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer	Cyclophosphamide Fludarabine	treatment	2	active_not_recruiting
NCT02381548	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	Adavosertib Belinostat	treatment	1	terminated
NCT00098826	SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	Ispinesib	treatment	1	completed
NCT00352365	Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia	Lenalidomide	treatment	2	completed
NCT05513131	Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML	Azacitidine Omacetaxine mepesuccinate Venetoclax	treatment	2	recruiting
NCT00305773	Vorinostat in Treating Patients With Acute Myeloid Leukemia	Vorinostat	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Decitabine Ipilimumab	treatment	1	active_not_recruiting
NCT00445744	Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Busulfan Cyclophosphamide Methotrexate Tacrolimus	treatment	Not Available	completed
NCT03009240	Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia	Decitabine Pevonedistat	treatment	1	active_not_recruiting
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT01798901	AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia	2'-Deoxycytidine AR-42 Decitabine	treatment	1	completed
NCT01640301	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Aldesleukin Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT02071901	Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy	Eltrombopag	supportive_care	2	unknown_status
NCT00079404	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	Tanespimycin	treatment	1	completed
NCT01707004	Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Azacitidine Busulfan Cyclophosphamide Decitabine Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01349972	Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Daunorubicin Mitoxantrone	treatment	2	completed
NCT03494569	Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome	Fludarabine Mechlorethamine	treatment	1	recruiting
NCT01801046	Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia	Cytarabine Mitoxantrone	treatment	1	terminated
NCT00459212	GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia	GTI-2040	treatment	1	completed
NCT00077181	3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies	Cytarabine Triapine	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT01861314	Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia	Bortezomib Bortezomib D-mannitol Decitabine Sorafenib	treatment	1	active_not_recruiting
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT04146038	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Azacitidine Decitabine Salsalate Venetoclax	treatment	2	completed
NCT02093403	Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine Escitalopram Selinexor	treatment	1	completed
NCT02316964	Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	2'-Deoxycytidine Aldesleukin Decitabine Natural Killer Cell	treatment	1	completed
NCT01361464	Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia	Tipifarnib	treatment	2	completed
NCT00795002	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	2	completed
NCT00101179	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Azacitidine Entinostat	treatment	1	completed
NCT01307579	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia	Caspofungin Fluconazole	supportive_care	3	completed
NCT01876953	Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia	Cytarabine Dasatinib Idarubicin	treatment	1 / 2	terminated
NCT02126553	Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission	Lenalidomide	treatment	2	completed
NCT02528877	Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	Fludarabine Mechlorethamine Ruxolitinib Sirolimus Tacrolimus	supportive_care	1	withdrawn
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00462605	MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	Entinostat Sargramostim	treatment	2	completed
NCT05584761	Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML	No drug interventions	treatment	1 / 2	recruiting
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT01203228	Dose-reduced Versus Standard Conditioning in MDS/sAML	No drug interventions	treatment	3	terminated
NCT01238211	Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Cytarabine Dasatinib Daunorubicin	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT01174888	Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia	Beta-D-Glucose Bortezomib Bortezomib D-mannitol Cytarabine Etoposide Midostaurin Mitoxantrone	treatment	1	completed
NCT00309907	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant	Etanercept Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00588809	Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia	Selumetinib	treatment	2	completed
NCT00988715	Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT05807932	Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML	Amsacrine Cytarabine Mycophenolate mofetil Tacrolimus Venetoclax	treatment	1 / 2	recruiting
NCT01567059	Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	2'-Deoxycytidine Cytarabine Decitabine Tosedostat	treatment	2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01139970	Veliparib and Temozolomide in Treating Patients With Acute Leukemia	Temozolomide Veliparib	treatment	1	active_not_recruiting
NCT01130506	Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cytarabine Decitabine Vorinostat	treatment	1	completed
NCT00331513	Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes	Idarubicin Vorinostat	treatment	1	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01627041	Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Decitabine	treatment	2	unknown_status
NCT02029417	Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	2'-Deoxycytidine Cytarabine Decitabine Omacetaxine mepesuccinate	treatment	2	terminated
NCT00369317	Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes	Asparaginase Escherichia coli Aspartic acid Cytarabine Daunorubicin Etoposide Tioguanine	treatment	3	completed
NCT00085124	Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	Cytarabine Daunorubicin	treatment	3	completed
NCT01028716	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	terminated
NCT00016016	Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	1 / 2	completed
NCT00042796	Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	2'-Deoxycytidine Decitabine	treatment	1	terminated
NCT02485535	Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	Escitalopram Selinexor	treatment	1	completed
NCT00045435	Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01132586	Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Cytarabine Idarubicin Lenalidomide	treatment	1	completed
NCT01465386	Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission	Bortezomib Bortezomib D-mannitol	treatment	2	terminated
NCT02809222	Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls	No drug interventions	health_services_research	Not Available	completed
NCT00096122	Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Cytarabine Idarubicin Tipifarnib	treatment	1 / 2	completed
NCT00096148	Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Bevacizumab Cytarabine Idarubicin	treatment	2	terminated
NCT03747757	Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue	No drug interventions	supportive_care	2	active_not_recruiting
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT02286726	CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	Cytarabine Daunorubicin	treatment	2	completed
NCT00407966	Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	Alvocidib Cytarabine Mitoxantrone	treatment	2	completed
NCT00119366	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00357565	Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	Busulfan Cyclosporine Filgrastim Fludarabine Melphalan Mycophenolate mofetil	treatment	2	active_not_recruiting
NCT02642965	Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia	Cytarabine Daunorubicin Filgrastim Fludarabine	treatment	1 / 2	completed
NCT04848974	Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia	Cladribine Cytarabine Uproleselan	treatment	1 / 2	active_not_recruiting
NCT00052520	Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	completed
NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	Azacitidine Ipilimumab Nivolumab	treatment	2	completed
NCT00049582	Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	1	terminated
NCT02634827	Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation	Decitabine Midostaurin	treatment	2	terminated
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT03630991	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Edetate calcium disodium anhydrous Edetic acid Succimer	treatment	1	recruiting
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT01839240	Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia	Azacitidine Cytarabine Mitoxantrone	treatment	1	completed
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Busulfan Cyclophosphamide Cyclosporine Fludarabine Methotrexate Mycophenolate mofetil Tacrolimus	treatment	3	completed
NCT00492401	Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia	2'-Deoxycytidine Decitabine	treatment	2	completed
NCT00087204	Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	Becatecarin Rebeccamycin	treatment	1	completed
NCT05139004	90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome	Basiliximab Fludarabine Indium Mechlorethamine Palifermin Yttrium Y-90	treatment	1	recruiting
NCT01300572	Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	Cyclosporine Fludarabine Indium Mycophenolate mofetil	treatment	1	completed
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT00217646	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	Sorafenib	treatment	1	completed
NCT04915612	Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia	Cytarabine Daunorubicin Gemtuzumab ozogamicin	treatment	1	active_not_recruiting
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT04620681	CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML	No drug interventions	treatment	1 / 2	active_not_recruiting
NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT02115295	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Cladribine Cytarabine Gilteritinib Idarubicin Midostaurin Venetoclax	treatment	2	recruiting
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01260714	Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia	Azacitidine Beta-D-Glucose Etoposide Mitoxantrone	treatment	1	terminated
NCT01760655	Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	1,4-Butanediol Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00475150	Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Cediranib	treatment	2	completed
NCT02085408	Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	Clofarabine Cytarabine Daunorubicin Decitabine	treatment	3	active_not_recruiting
NCT00301938	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes	7-Hydroxystaurosporine Perifosine	treatment	1	completed
NCT01041443	5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	5-fluoro-2'-deoxycytidine Tetrahydrouridine	treatment	1	completed
NCT00531232	A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)	Clofarabine	treatment	2	completed
NCT00209833	Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T	Cytarabine Daunorubicin Etoposide Filgrastim Fludarabine Idarubicin	treatment	2 / 3	unknown_status
NCT00715637	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study	Amonafide Cytarabine Daunorubicin	treatment	3	unknown_status